https://www.selleckchem.com/products/Eloxatin.html
83) or progression-free survival (PFS) (P = .61) across the 2 cohorts. No significant association between the use of rituximab and risk of relapse (P = .15) or nonrelapse mortality (P = .12) was observed. Variables independently associated with lower OS included older age at auto-HCT (P less then .001), absence of CR at auto-HCT (P less then .001) and early chemoimmunotherapy failure (P less then .001). Older age (P less then .0002) and non-CR pre-HCT (P less then .0001) were also associated with inferior PFS. There was no significant
Aimer
Commentaire
Partagez
